Pharmaceutical The past week saw a bundle of fourth-quarter and full year financials from the biotech and pharma sector this week, with one factor paramount, especially US companies. Changes in currency year over year are wreaking havoc on the absolute numbers. That fact is that businesses with a lot of international business are hurting from the stronger dollar. 30 January 2016